Pain News and Research

Latest Pain News and Research

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Positive results from BioSpecifics’ XIAFLEX Phase III clinical program on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced positive top-line results from the IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) Phase III clinical program of XIAFLEX for the treatment of Peyronie's disease, which was conducted by BioSpecifics' partner Auxilium Pharmaceuticals, Inc.

5 Jun 2012

ProStrakan, Orexo reconfigure commercial rights to Abstral

Orexo AB and ProStrakan Group plc jointly announce today that the companies have reconfigured the commercial rights to the product, Abstral, in various territories worldwide.

4 Jun 2012

AcelRx completes private placement of common stock

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that it completed its previously announced private placement of common stock and warrants to purchase common stock on June 1, 2012.

4 Jun 2012

First Edition: June 4, 2012

Today's headlines include the latest news on implementation of the health law, on the pending Capitol Hill effort to repeal the medical device tax and reports from the states.

4 Jun 2012

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

4 Jun 2012

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

The antidepressant drug duloxetine, known commercially as Cymbalta, helped relieve painful tingling feelings caused by chemotherapy in 59 percent of patients, a new study finds. This is the first clinical trial to find an effective treatment for this pain.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus prednisone.

4 Jun 2012

Reumofan Plus may have harmful pharmaceutical ingredients, warns FDA

The U.S. Food and Drug Administration is warning consumers that Reumofan Plus, marketed as a "natural" dietary supplement for pain relief and other serious conditions, contains several active pharmaceutical ingredients not listed on the label that could be harmful.

2 Jun 2012

Local anesthetic mixed with magnetized 'ferrofluids' may prevent rare complication of spinal anesthesia

An simple technique using local anesthetic mixed with magnetized "ferrofluids" may provide a new approach to preventing a rare but serious complication of spinal anesthesia, reports the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jun 2012

Cardinal Health to produce new AD diagnostic imaging agent, Amyvid

Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.

2 Jun 2012

Pisgah receives USPTO Notice of Allowance for drug abuse solution

Pisgah Laboratories, Inc. received Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose Dumping Properties."

2 Jun 2012

Exercise reduces expression of cytokines and alleviates neuropathic pain

Exercise helps to alleviate pain related to nerve damage (neuropathic pain) by reducing levels of certain inflammation-promoting factors, suggests an experimental study in the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jun 2012

New medication proves effective in slowing the spread of metastatic prostate cancer

A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.

2 Jun 2012

Several key discoveries in palliative care

What is the best way to talk to someone about prognosis and quality of life when serious illness strikes? It turns out that no one had studied that question through direct observation, until the University of Rochester Medical Center audio-recorded 71 palliative care discussions.

2 Jun 2012

Lilly, Kowa announce results from PREVAIL U.S. study

Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company today announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated the efficacy of LIVALO (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed dyslipidemia.

2 Jun 2012

Hip arthroplasty pseudotumors ‘cause for great concern’

Pseudotumors may be 10 times more common in patients after metal-on-metal hip resurfacing and total hip replacement than thought, suggest Dutch researchers.

1 Jun 2012

Senate field hearing probes whether Accretive Health's bill collection practices violated patient privacy

Sen. Al Franken, D-Minn., who convened the hearing, questioned whether thousands of Minnesotans who trusted their health records to Minnesota's Fairview and North Memorial hospitals, suffered privacy breaches. The hearing follows an investigation by Minnesota's attorney general into the relationship between Accretive Health and Fairview.

1 Jun 2012

Viewpoints: Bishops' request for contraception exemption may push legal precedent; Maine's experiment on health care

43 Roman Catholic organizations have filed lawsuits challenging a ... regulation that requires employers or their health insurers to offer birth control coverage to workers. The plaintiffs say that complying with the regulation would violate their religious freedom.

1 Jun 2012

Pain News and Research

Latest Pain News and Research

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Positive results from BioSpecifics’ XIAFLEX Phase III clinical program on Peyronie's disease

ProStrakan, Orexo reconfigure commercial rights to Abstral

AcelRx completes private placement of common stock

First Edition: June 4, 2012

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Reumofan Plus may have harmful pharmaceutical ingredients, warns FDA

Local anesthetic mixed with magnetized 'ferrofluids' may prevent rare complication of spinal anesthesia

Cardinal Health to produce new AD diagnostic imaging agent, Amyvid

Pisgah receives USPTO Notice of Allowance for drug abuse solution

Exercise reduces expression of cytokines and alleviates neuropathic pain

New medication proves effective in slowing the spread of metastatic prostate cancer

Several key discoveries in palliative care

Lilly, Kowa announce results from PREVAIL U.S. study

Hip arthroplasty pseudotumors ‘cause for great concern’

Senate field hearing probes whether Accretive Health's bill collection practices violated patient privacy

Viewpoints: Bishops' request for contraception exemption may push legal precedent; Maine's experiment on health care

Forensics and toxicology - Industry Focus eBook eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Pain News and Research

Latest Pain News and Research

Forensics and toxicology - Industry Focus eBook eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in